Clinical MedicineUpdated Aug 20, 2026Version v1
Reviewed milestones, validation shifts, standards, datasets, and debates linked to public evidence.
Evidence from New England Journal of Medicine indicates that Permanent restoration of a transparent, renewing corneal epithelium was achieved in 76.6% of treated eyes. This is tracked as a clinical because it changes how Regenerative medicine and stem cell therapies is understood, validated, or applied.
Evidence from Expert Opinion on Biological Therapy indicates that Major trend: Alternative reprogramming techniques for induced pluripotent stem cells (iPSCs). This is tracked as a clinical because it changes how Regenerative medicine and stem cell therapies is understood, validated, or applied.
Evidence from Materials indicates that Alginate is biocompatible and biodegradable, suitable for various biomedical applications. This is tracked as a review because it changes how Regenerative medicine and stem cell therapies is understood, validated, or applied.
Evidence from Science Translational Medicine indicates that 88% complete response rate in B-ALL patients treated with 19-28z CAR T cells. This is tracked as a standard because it changes how Regenerative medicine and stem cell therapies is understood, validated, or applied.
Evidence from Cochrane Database of Systematic Reviews indicates that Cell treatment did not significantly alter the risk of all-cause mortality. This is tracked as a standard because it changes how Regenerative medicine and stem cell therapies is understood, validated, or applied.
Evidence from Stem Cell Research & Therapy indicates that iPSCs offer a valuable resource for regenerative medicine and disease modeling. This is tracked as a clinical because it changes how Regenerative medicine and stem cell therapies is understood, validated, or applied. It is supported by 2 papers in the same timeline signal.
Evidence from Stem Cell Research & Therapy indicates that MSC-based cell-free therapies avoid potential issues associated with cell transplantation like tumorigenicity and immune rejection. This is tracked as a clinical because it changes how Regenerative medicine and stem cell therapies is understood, validated, or applied.
Evidence from Cells indicates that iPSCs offer an ethical alternative to embryonic stem cells (ESCs). This is tracked as a clinical because it changes how Regenerative medicine and stem cell therapies is understood, validated, or applied.
Evidence from Stem Cell Research & Therapy indicates that Stem cells show promise for treating interstitial lung disease due to their pluripotency and paracrine actions. This is tracked as a clinical because it changes how Regenerative medicine and stem cell therapies is understood, validated, or applied.
Evidence from Stem Cell Research & Therapy indicates that Stem cell research has seen revolutionary developments, including gene editing tools like CRISPR-Cas9. This is tracked as a standard because it changes how Regenerative medicine and stem cell therapies is understood, validated, or applied.
Evidence from Cell Transplantation indicates that HUCMSCs offer advantages over bone marrow stem cells, including painless collection and faster self-renewal. This is tracked as a clinical because it changes how Regenerative medicine and stem cell therapies is understood, validated, or applied.
Evidence from Stem Cells International indicates that MSC therapy shows promising safety and beneficial outcomes in vivo. This is tracked as a controversy because it changes how Regenerative medicine and stem cell therapies is understood, validated, or applied.